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Long-term Prognostic Value
of Dobutamine Stress
99mTc-Sestamibi SPECT:
Single-Center Experience
with 8-year Follow-up1
PURPOSE: To determine the long-term prognostic value of dobutamine stress
technetium 99m (99mTc)-labeled sestamibi single photon emission computed to-
mography (SPECT) in patients with limited exercise capacity.
MATERIALS AND METHODS: Clinical data and SPECT results were analyzed in
531 consecutive patients. Follow-up was successful in 528 (99.4%) patients; 55
underwent early revascularization and were excluded. Normal or abnormal findings
were considered in the absence or presence of fixed and/or reversible perfusion
defects. A summed stress score was calculated to estimate the extent and severity of
perfusion defects. Univariate and multivariate Cox proportional hazards regression
models were used to identify independent predictors of late cardiac events. The
incremental value of myocardial perfusion scintigraphy over clinical variables in
predicting events was determined according to two models. The probability of
survival was calculated by using the Kaplan-Meier method.
RESULTS: Findings were abnormal in 312 patients. During 8.0 years  1.5 of
follow-up (range, 4.5–10.6 years), cardiac death occurred in 67 patients (total
deaths, 165); nonfatal myocardial infarction, in 34; and late revascularization, in 49.
The annual rates for cardiac death, cardiac death or infarction, and all events were
0.9%, 1.2%, and 1.5%, respectively, after normal findings and 2.7%, 3.4%, and
4.4%, respectively, after abnormal findings (P  .05). In a multivariable Cox pro-
portional hazards model, not only an abnormal finding but also the summed stress
score provided incremental prognostic information in addition to clinical data. The
hazard ratio for cardiac death was 1.09 (95% CI: 1.01, 1.18) per 1-unit increment
of the summed stress score.
CONCLUSION: The incremental prognostic value of dobutamine stress 99mTc-
sestamibi SPECT over clinical data was maintained over an 8-year follow-up in
patients with limited exercise capacity.
© RSNA, 2002
The primary goal of risk stratification in patients suspected of having or known to have
coronary arterial disease is to distinguish patients at high risk of the disease who may
benefit from further invasive strategies from low-risk patients who do not require further
invasive evaluation. Myocardial perfusion imaging with administration of technetium
99m (99mTc)-labeled sestamibi during dobutamine-induced patient stress provides useful
information for risk stratification and determination of optimal clinical management
(1–3). The investigators in multiple studies (4–7) have reported the prognostic value of
99mTc-sestamibi myocardial perfusion imaging in various patient subsets at short- to
intermediate-term follow-up. To overcome reduced exercise capacity and therefore insuf-
ficient testing, various types of non–exercise-dependent pharmacologic stressors, such as
adenosine and dobutamine, were developed in conjunction with myocardial perfusion
imaging.
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However, it is important to note that
to our knowledge, no findings of long-
term prognostic studies involving 99mTc-
sestamibi myocardial perfusion imaging
are currently available (1–7). The purpose
of our study was to determine the long-
term prognostic value of dobutamine
stress 99mTc-sestamibi SPECT findings in
patients with limited exercise capacity.
MATERIALS AND METHODS
Study Population
The study population comprised 531
consecutive patients with limited exer-
cise capacity who were referred between
1990 and 1995 for dobutamine stress
99mTc-sestamibi SPECT for the evaluation
of suspected or known coronary arterial
disease. Follow-up was successful in 528
(99.4%) of 531 patients. Fifty-five patients
underwent early coronary revasculariza-
tion (35 with coronary arterial bypass
graft placement and 20 with percutane-
ous transluminal coronary angioplasty)
60 days after scintigraphy and were ex-
cluded from analysis. In these patients,
the decision to revascularize had already
been made, and the test was performed as
part of a research protocol. As a result,
prognostic data reported are based on
473 patients. All patients gave informed
consent before testing. The local medical
ethics committee approved the study
protocol.
In all patients, a structured interview
was performed and a clinical history ob-
tained, including assessment of cardiac
risk factors, prior to dobutamine stress
testing. Hypertension was defined as
blood pressure of 140/90 mm Hg or
greater or treatment with antihyperten-
sive medication. Diabetes mellitus was
defined as a fasting glucose level of 7.8
mmol/L or higher or the need for insulin
or oral hypoglycemic agents. Hypercho-
lesterolemia was defined as a total cho-
lesterol level of 6.4 mmol/L or higher or
as treatment with lipid-lowering medica-
tion.
Dobutamine Stress Protocol
Stress testing after dobutamine admin-
istration was performed as described pre-
viously (8). Dobutamine hydrochloride
(Dobutamine; Centrafarm Services, Et-
ten-Leur, the Netherlands) was injected
intravenously, first at a dose of 10 g per
kilogram of body weight per minute for 3
minutes; the dose was then increased by
10 g/kg/min every 3 minutes up to a
maximum dose of 40 g/kg/min. If the
test end point was not reached at a do-
butamine dose of 40 g/kg/min, up to 1
mg of atropine sulfate (Atropine; Centra-
farm Services) was administered intrave-
nously. Blood pressure, heart rate, and
electrocardiographic (ECG) findings were
continuously monitored. Test end points
were achievement of target heart rate
(85% of maximum age and sex-predicted
heart rate); horizontal or downsloping ST
segment depression of more than 2 mm
at an interval of 80 msec after the J point,
as compared with the baseline measure-
ment; ST segment elevation greater than
1 mm in patients without previous myo-
cardial infarction (MI); severe angina;
systolic blood pressure decrease greater
than 40 mm Hg, as compared with the
baseline measurement; blood pressure
higher than 240/120 mm Hg; or clini-
cally important cardiac arrhythmias.
Intravenously administered metoprolol
tartrate (Metoprolol, Selokeen IV; Astra-
Zeneca, Zoetermeer, the Netherlands)
was available to reverse the side effects
of dobutamine, and atropine was used
if the effects did not revert spontane-
ously after termination of dobutamine
infusion. Side effects were registered,
and the relationship between cardiac
arrhythmias during testing and subse-
quent cardiac events was evaluated.
SPECT Image Acquisition and
Interpretation
A dose of 370 MBq of 99mTc-sestamibi
(Cardiolite; Bristol-Myers Squibb Pharma
Belgium, Brussels, Belgium) was admin-
istered intravenously approximately 1
minute prior to termination of the stress
test. For studies performed with the patient
at rest, 370 MBq of sestamibi was injected
at least 24 hours after the stress test. Images
were acquired with a Gammasonics single-
head Rota camera (Orbiter; Siemens, Iselin,
NJ) without attenuation or scatter correc-
tion, by using a low-energy all-purpose col-
limator. Thirty-two projections were ob-
tained over a 180° arc, from left posterior
oblique to right anterior oblique, with an
acquisition time of 45 seconds per projec-
tion. Data were collected in a 64  64 ma-
trix (word mode), and images were recon-
structed by using a filtered backprojection
algorithm and a ramp reconstruction filter.
Transverse images were reconstructed by
using a software package (SPETS; Nuclear
Diagnostics, Ha¨gersten, Sweden). From the
three-dimensional data, oblique (short-
axis) and sagittal (vertical long-axis) images
obtained perpendicular and parallel to the
long axis, respectively, were reconstructed.
For each study, six oblique sections were
defined from the apex to the base, and
three sagittal sections were defined. Each of
the six short-axis sections was divided into
eight equal segments. The septal part of the
two basal sections was excluded from anal-
ysis because this region corresponds to the
fibrous portion of the interventricular sep-
tum and normally exhibits reduced up-
take. Therefore, a total of 47 segments were
identified (three long axis and 44 short
axis). Scans were semiquantitatively inter-
preted by using visual analysis assisted
by circumferential profile analysis. Profile
curves 2.5 SDs below normal perfusion
were considered abnormal.
Images obtained at stress and rest were
reviewed side by side at a computer dis-
play with consensus reading by two ex-
perienced observers who were unaware
of the patients’ clinical data. In case of
disagreement, a majority decision was
achieved by consulting a third observer.
In this study, the original interpretations
of the images were used. A reversible per-
fusion defect was defined as a perfusion
defect on stress images that partially or
completely resolved at rest on two or
more contiguous segments or sections in
the 47-segment model. A fixed perfusion
defect was defined as a perfusion defect
on stress images on two or more contig-
uous segments or sections that persisted
on rest images in the 47-segment model.
Findings were designated as abnormal in
the presence of a fixed and/or reversible
perfusion defect.
To assess the severity of perfusion ab-
normalities, the left ventricular myocar-
dium was divided into six segments: an-
terior, inferior, septal anterior, septal
posterior, posterolateral, and apical. Each
of the six major left ventricular segments
was assigned a score by using a four-point
system: 0, normal (100%  tracer activ-
ity  75%); 1, slightly reduced (75% 
tracer activity  50%); 2, moderately re-
duced (50%  tracer activity  25%); or
3, severely reduced or absent uptake
(25%  tracer activity  0%). A summed
stress score (SSS) was obtained by adding
the scores of the six myocardial segments
during stress. The SSS incorporates the
extent and severity of a perfusion defect.
Follow-up
Follow-up data were collected in 2001.
One author (A.F.L.S.) contacted patients’
general practitioners and/or reviewed hos-
pital records. This author was blinded to
scanning results. The date of the last exam-
ination or consultation was used to deter-
mine follow-up. The mean follow-up was
8.0 years 1.4 (range, 4.5–10.6 years). End
points were overall deaths (death from all
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causes), cardiac death, nonfatal MI, or late
(60 days) coronary revascularization.
Cardiac death was defined as death caused
by acute MI, clinically important cardiac
arrhythmias, or refractory congestive heart
failure, together with ECG and autopsy re-
sults, when available. Sudden death occur-
ring without another explanation was in-
cluded as cardiac death. Cardiac enzyme
levels and ECG changes were used to de-
fine nonfatal MI. Patients were censored at
the time of late coronary revascularization.
Statistical Analysis
Values were expressed as means  SDs
or numbers and were compared by using
the Student t test or 2 test. Univariate
and multivariate Cox proportional haz-
ards regression models (BMDP Statistical
Software, Los Angeles, Calif) were used to
identify independent predictors of late
cardiac events (9). Variables were selected
in a stepwise forward selection manner,
with entry and retention set with a P
value of .05 considered to indicate a sig-
nificant difference. A variable’s risk was
expressed as a hazard ratio with a corre-
sponding 95% CI. The incremental value
of myocardial perfusion scintigraphy
over the clinical variables in the predic-
tion of events was calculated according
to two models. In model 1, the only scan-
ning variable entered was an abnormal
finding. In model 2, scanning variables,
including SSS and the presence of a fixed
or reversible defect, were entered. The
probability of survival was calculated by
using the Kaplan-Meier method, and sur-
vival curves were compared by using the
log-rank test. A P value less than .05 was
considered to indicate a statistically sig-
nificant difference.
RESULTS
Patient Demographics and Stress
Testing Results
The characteristics of the 473 patients
(273 men; mean age, 61 years  12 [SD])
are presented in Table 1. There was a
significant increase in heart rate (70 beats
per minute 14 to 136 beats per minute
17, P  .001) and systolic blood pressure
(140 mm Hg  23 to 146 mm Hg  31,
P  .001) during dobutamine stress test-
ing. The highest dobutamine dose was
10 g  kg1  min1 in three (1%) pa-
tients, 20 g  kg1  min1 in 15 (3%),
30 g  kg1  min1 in 66 (14%), and 40
g  kg1  min1 in 389 (82%). In 196
(41%) patients, atropine was added. Pa-
tients who were receiving beta blockers
(120 [65%] of 185) more frequently re-
ceived atropine than those who were
not receiving beta blockers (76 [26%] of
288, P  .001). Test findings were in-
conclusive (failure to achieve target
heart rate in the absence of perfusion
abnormalities) in 43 (9%) patients.
Prognostic data reported were based on
473 patients, including the 43 who did
not achieve the target heart rate. No
patient experienced MI or ventricular
fibrillation. Side effects were atrial fi-
brillation in five (1%) patients, short
ventricular tachycardia (10 com-
plexes) in 19 (4%), severe hypotension
(decrease in systolic blood pressure 
40 mm Hg) in three (0.6%), and severe
hypertension (blood pressure  240/130
mm Hg) in three (0.6%). Minor side ef-
fects included nausea in 18 (4%), chills in
22 (5%), and headache in 29 (6%). No
relationship was observed between car-
diac arrhythmias during the test and sub-
sequent cardiac events; the hazard ratio
was 1.3 (range, 0.8–2.0).
SPECT and Follow-up Results
SPECT images were abnormal in 312
(66%) of 473 patients. Perfusion abnor-
malities were reversible in 72 (15%), fixed
in 126 (27%), and both fixed and revers-
ible (or partially reversible) in 114 (24%)
patients. During follow-up, 165 (35%)
deaths occurred, of which 67 (41%) were
due to cardiac causes. Nonfatal MI oc-
curred in 34 (7%) patients. Forty-nine
(10%) patients underwent late (60
days) coronary revascularization (coro-
nary arterial bypass graft placement, 28
patients; percutaneous transluminal cor-
onary angioplasty, 21 patients). All 49
patients had abnormal SPECT findings,
and 43 (88%) of the 49 had reversible
perfusion defects.
Predictive Value of Clinical Data
and Test Results
Univariate and multivariate predictors
of cardiac events are presented in Tables
2 and 3. The annual event rates for car-
diac death, cardiac death or nonfatal MI,
and all events were 0.9%, 1.2%, and
1.5%, respectively, for patients with nor-
mal findings and 2.7%, 3.4%, and 4.4%
for patients with abnormal findings.
Kaplan-Meier survival curves are pre-
sented in Figures 1–3. The survival curves
indicate that patients with normal sesta-
mibi SPECT findings after induced stress
maintained a low event rate up to 8 years
after stress testing. Figure 4 demonstrates
the incremental prognostic value of do-
butamine stress sestamibi SPECT findings
over clinical data. An abnormal perfusion
pattern, as well as the SSS, provided ad-
ditional incremental prognostic informa-
tion. The hazard ratio for cardiac death
was 1.09 (range, 1.01–1.18) per 1-unit in-
crement of the SSS. There was no further
Figure 1. Kaplan-Meier survival curves for cardiac death according to results of dobutamine
stress 99mTc-sestamibi SPECT. The curves indicate that patients with normal stress images main-
tained a low event rate up to 8 years after stress testing.
TABLE 1
Characteristics of Study Population
Characteristic
No. of Patients
(n  473)
Male sex 273 (58)
Hypertension 214 (45)
Diabetes mellitus 69 (15)
Smoking 122 (26)
Hypercholesterolemia 116 (25)
Congestive heart failure 84 (18)
Beta-blocker use 185 (39)
Prior MI 210 (44)
Prior revascularization
Surgical 92 (19)
Percutaneous 75 (16)
Note.—The mean patient age was 61 years 
12. Numbers in parentheses are percentages.
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increase of the hazard ratio if the SSS was
greater than 9.
DISCUSSION
Risk stratification in patients known to
have or suspected of having coronary arte-
rial disease is essential for optimal clinical
decision making (10). The prognostic value
of imaging during stress and after admin-
istration of technetium has been reported
in various patient subsets at short-to inter-
mediate-term follow-up (2-7). The mean
follow-up in the current study was 8.0
years  1.4, as compared with an average
follow-up of 0.8–3.6 years after exercise
and 0.8–2.3 years after myocardial perfu-
sion imaging with sestamibi during phar-
macologic stress among previous studies
(2–7). The main finding from the current
study was that the prognostic value of do-
butamine stress 99mTc-sestamibi SPECT
was maintained at long-term follow-up.
Univariate and multivariate Cox propor-
tional regression analysis demonstrated
that sestamibi SPECT provided incremen-
tal prognostic information in addition to
clinical and stress test parameters through
a nearly complete 8-year follow-up period.
Patients with normal examination find-
TABLE 2
Predictors of Cardiac Death at Univariate and Multivariate Analysis
Predictors Univariate Analysis
Multivariate Analysis
Clinical Data Model 1 Model 2
Clinical characteristics
Age* 1.03 (1.01, 1.06) 1.03 (1.01, 1.05) 1.02 (1.01, 1.04) 1.03 (1.01, 1.05)
Male sex 2.4 (1.4, 4.1) 2.5 (1.6, 3.9) 2.1 (1.3, 3.3) 2.3 (1.4, 3.6)
Prior MI 2.0 (1.2, 3.3) NS NS NS
Diabetes mellitus 2.3 (1.3, 4.0) 1.8 (1.1, 2.8) 1.7 (1.1, 2.7) 1.7 (1.1, 2.8)
Hypertension 0.7 (0.4, 1.2) NS NS NS
Hypercholesterolemia 0.9 (0.5, 1.5) NS NS NS
Typical angina 1.1 (0.6, 1.9) NS NS NS
Smoking 1.6 (0.9, 2.6) NS NS NS
Congestive heart failure 4.7 (2.9, 7.6) 2.1 (1.4, 3.2) 1.9 (1.2, 2.8) 1.7 (1.1, 2.7)
Stress test results
Typical angina 1.0 (0.6, 1.7) NA NS NS
ST segment changes 1.5 (0.9, 2.5) NA NS NS
Scanning parameters
Abnormal scan 3.4 (1.7, 6.8) NA 2.1 (1.2, 3.7) NA
SSS* 1.22 (1.13, 1.32) NA NA 1.09 (1.01, 1.18)
Fixed defect 1.8 (1.1, 2.9) NA NA NS
Reversible defect 1.2 (0.8, 2.0) NA NA NS
Note.—Values are Cox proportional hazards ratios; numbers in parentheses are 95% CIs. In model 1, the only scanning variable entered was the
presence of an abnormal scan. In model 2, the SSS and the presence of a fixed or reversible defect were included. NA  not applicable, NS  not
significant.
* Per 1-unit increment; indicates variable excluded.
TABLE 3
Predictors of Cardiac Events (cardiac death, nonfatal MI, or revascularization) at Univariate and Multivariate Analysis
Predictors Univariate Analysis
Multivariate Analysis
Clinical Data Model 1 Model 2
Clinical characteristics
Age* 1.02 (1.00, 1.04) 1.03 (1.01, 1.05) 1.02 (1.01, 1.04) 1.03 (1.01, 1.05)
Male sex 2.5 (1.6, 3.8) 2.5 (1.6, 3.9) 2.1 (1.3, 3.3) 2.3 (1.4, 3.6)
Prior MI 2.2 (1.5, 3.2) NS NS NS
Diabetes mellitus 1.9 (1.2, 3.0) 1.8 (1.1, 2.8) 1.7 (1.1, 2.7) 1.7 (1.1, 2.8)
Hypertension 0.7 (0.5, 1.1) NS NS NS
Hypercholesterolemia 1.1 (0.7, 1.7) NS NS NS
Typical angina 1.1 (0.7, 1.7) NS NS NS
Smoking 1.2 (0.8, 1.9) NS NS NS
Congestive heart failure 2.7 (1.8, 4.1) 2.1 (1.4, 3.2) 1.9 (1.2, 2.8) 1.7 (1.1, 2.7)
Stress test results
Typical angina 1.1 (0.7, 1.6) NA NS NS
ST segment changes 1.6 (0.8, 1.8) NA NS NS
Scanning parameters
Abnormal scan 3.2 (1.9, 5.4) NA 2.1 (1.2, 3.7) NA
SSS* 1.17 (1.10, 1.25) NA NA 1.09 (1.01, 1.18)
Fixed defect 1.4 (1.0, 2.1) NA NA NS
Reversible defect 1.4 (1.0, 2.1) NA NA NS
Note.—Values are expressed as Cox proportional hazards ratios and 95% CIs. In model 1, the only scanning variable entered was the presence of an
abnormal scan. In model 2, the SSS and the presence of a fixed or reversible defect were included. NA  not applicable, NS  not significant.
* Per 1-unit increment, indicates variable excluded.
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ings had a good long-term prognosis, and
in contrast, patients with abnormal find-
ings had an increased risk of future cardiac
events. An abnormal perfusion pattern, as
well as SSS, provided additional incremen-
tal prognostic information.
Long-term Prognostic Value
Although the findings of long-term
prognostic studies are currently not avail-
able, the medium-term prognostic value
of dobutamine stress sestamibi SPECT
has been reported in several studies (4–
7). Geleijnse et al (4) examined 392 pa-
tients, with a median follow-up of 22
months  13. Twenty-seven (7%) pa-
tients died of cardiac-related causes dur-
ing follow-up, 17 (4%) had nonfatal MIs,
and 34 (9%) underwent late coronary re-
vascularization. The hard cardiac event
(cardiac death or nonfatal MI) rates were
0.8% per year in patients with normal
examination findings and 9.2% per year
in those with abnormal dobutamine
stress sestamibi SPECT scintigraphic find-
ings.
The medium-term prognosis of women
with chest pain and normal dobutamine
stress sestamibi SPECT images is excellent
(5). None of the study population of 80
women died or had a nonfatal MI during
the follow-up of 23 months  13. Senior
et al (6) followed up 61 patients under-
going coronary angiography and dobu-
tamine stress sestamibi SPECT for 19
months  11. There were two (3%)
deaths, two (3%) nonfatal MIs, 13 (21%)
cases of unstable angina, and three (5%)
cases of congestive heart failure during
follow-up. The event rate was 3% in pa-
tients with normal results and 44% in
patients with abnormal results. Recently,
Calnon et al (7) studied 308 patients at
high risk for cardiac events who under-
went dobutamine stress sestamibi SPECT.
During an average follow-up of 1.9
years  1.1, 15 patients died of cardiac
causes and 18 had MIs. Event rates were
10.0% in patients with abnormal SPECT
images and 2.3% in those with normal
results.
The findings of the present study ex-
tend the conclusions drawn from the
four medium-term prognostic studies
(4–7). In the current study population
of 473 patients, the prognostic value of
dobutamine stress sestamibi SPECT im-
aging was maintained over an 8-year
period. The event rates for cardiac
death, cardiac death or nonfatal MI,
and all events were, respectively, 0.9%,
1.2%, and 1.5% per year for patients
with normal results and 2.7%, 3.4%,
and 4.4% per year for those with abnor-
mal results. Moreover, Kaplan-Meier sur-
vival curves continued to diverge over
time, whereas the curve for patients with
normal SPECT findings showed favorable
event-free survival, indicating that the
prognostic value was maintained during
the entire follow-up period. This is par-
ticularly relevant, since some investiga-
tors have recently suggested that the
“warranty” period for normal findings of
sestamibi imaging after stress appears to
be 2 years (2). In contrast, findings of the
present study indicate that patients with
normal findings of sestamibi imaging af-
ter stress have a durable good prognosis
up to 8 years after index stress testing.
The annual event rate for cardiac death
Figure 3. Bar graph shows incremental prog-
nostic value of dobutamine stress 99mTc-sesta-
mibi SPECT over clinical data. Dobutamine
stress 99mTc-sestamibi SPECT provided signifi-
cant prognostic information in addition to
clinical data alone.
Figure 4. Bar graph shows cumulative cardiac event (cardiac death, nonfatal MI, or revascular-
ization) rates per year according to SSS. An abnormal perfusion pattern, as well as the SSS,
provided additional incremental prognostic information.
Figure 2. Kaplan-Meier survival curves for cardiac events (cardiac death, nonfatal MI, or revas-
cularization), according to results of dobutamine stress 99mTc-sestamibi SPECT. The annual
cardiac event rate was significantly lower in patients with normal perfusion.
Volume 225  Number 3 Dobutamine Stress SPECT: Long-term Prognostic Value  705
R
a
d
io
lo
gy
or nonfatal MI in patients with normal
scintigraphic results was comparable
with the event rate in the general popu-
lation. Hence, patients with normal
SPECT images can be spared further inva-
sive evaluation of their coronary anat-
omy. However, the clinical value and op-
timal intervals of periodic stress testing
in these patients deserve further investi-
gation.
Incremental Prognostic Value
In this study, a multivariate Cox re-
gression model demonstrated that do-
butamine stress sestamibi SPECT had an
incremental prognostic value in addi-
tion to prognostic information from
clinical data and stress testing. This is
in agreement with the findings ob-
tained in long-term follow-up studies in
which thallium 201 SPECT was used to
stratify patients (10–14). Independent
clinical predictors of cardiac events
were age, male sex, diabetes mellitus,
and congestive heart failure. Typical
angina was not independently predic-
tive of events, perhaps because of di-
minished physical activity in a popula-
tion with a limited exercise capacity.
The incremental value of myocardial
perfusion scintigraphy over the clinical
variables in the prediction of events
was determined according to two mod-
els: In the first model, abnormal find-
ings were a powerful independent scin-
tigraphic predictor of future cardiac
events. The second model demon-
strated that the SSS was additive to clin-
ical parameters and to hemodynamic
and ECG parameters. This indicates
that the long-term prognosis is related
not only to the presence but also to the
extent and severity of perfusion defects
on dobutamine stress sestamibi SPECT
scans.
Limitations
The diagnostic value of dobutamine
stress sestamibi SPECT was high; how-
ever, 9% of patients had inconclusive
findings (failure to achieve the target
heart rate or to demonstrate a perfusion
abnormality). Therefore, the diagnostic
and perhaps the prognostic value could
have been even higher if beta-blocker
medication had been routinely withheld
before stress testing.
In conclusion, the incremental prognos-
tic value of dobutamine stress 99mTc-sesta-
mibi SPECT findings over clinical data is
maintained at long-term follow-up. Pa-
tients with normal test results have a good
long-term prognosis and thus may not re-
quire further invasive evaluation.
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